Robert J Mullin
Overview
Explore the profile of Robert J Mullin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hall J, Marlow L, Mathias A, Dawson L, Durham W, Meshaw K, et al.
J Transl Med
. 2016 May;
14(1):129.
PMID: 27165126
Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for <1 % of all pancreatic neoplasms. Very few retrospective studies are available to help guide management. We previously...
2.
Rheault T, Caferro T, Dickerson S, Donaldson K, Gaul M, Goetz A, et al.
Bioorg Med Chem Lett
. 2008 Dec;
19(3):817-20.
PMID: 19111461
Two new series of potent and selective dual EGFR/ErbB-2 kinase inhibitors derived from novel thienopyrimidine cores have been identified. Isomeric thienopyrimidine cores were evaluated as isosteres for a 4-anilinoquinazoline core...
3.
Molina J, Kaufmann S, Reid J, Rubin S, Galvez-Peralta M, Friedman R, et al.
Clin Cancer Res
. 2008 Dec;
14(23):7900-8.
PMID: 19047120
Purpose: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members....
4.
Stevens K, Alligood K, Alberti J, Caferro T, Chamberlain S, Dickerson S, et al.
Bioorg Med Chem Lett
. 2008 Nov;
19(1):21-6.
PMID: 19028424
A novel class of pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines has been identified which potently inhibit the EGFR and ErbB-2 receptor tyrosine kinases. Synthetic modifications of the pyrrolidine carbamate moiety result in a range...
5.
Kenley R, Denissenko M, Mullin R, Story J, Ekblom J
Oncol Rep
. 2008 Apr;
19(5):1113-21.
PMID: 18425366
Our study probed the effects of the beta-2 adrenergic agonist, formoterol and the macrolide antibiotic, roxithromycin, on muscle wasting in a well-characterized animal model of cancer cachexia. Female Wistar rats...
6.
Kumar R, Knick V, Rudolph S, Johnson J, Crosby R, Crouthamel M, et al.
Mol Cancer Ther
. 2007 Jul;
6(7):2012-21.
PMID: 17620431
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy correlates with the modulation of desired/intended target in vivo....
7.
Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M, et al.
Cancer Res
. 2006 Feb;
66(3):1630-9.
PMID: 16452222
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of lapatinib by testing its effect on...
8.
Gaul M, Guo Y, Affleck K, Cockerill G, Gilmer T, Griffin R, et al.
Bioorg Med Chem Lett
. 2003 Mar;
13(4):637-40.
PMID: 12639547
We have identified a novel class of 6-thiazolylquinazolines as potent and selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity, with IC(50) values in the nanomolar range. These compounds...
9.
Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D, et al.
Oncogene
. 2002 Sep;
21(41):6255-63.
PMID: 12214266
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small molecule, GW572016, potently...